Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease

Cold Spring Harbor Perspectives in Medicine

Volumn 2, Issue 3, 2012, Pages

  Goel, Shom ^a   Wong, Andus Hon Kit ^a   Jain, Rakesh K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANGIOGENIC FACTOR; ANGIOPOIETIN; BETA INTERFERON; BEVACIZUMAB; CEDIRANIB; CYTOKINE; GROWTH FACTOR; INTEGRIN; LAPATINIB; MONOCLONAL ANTIBODY DC101; NITRIC OXIDE SYNTHASE; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR B; SEMAPHORIN; SEX HORMONE; THROMBOSPONDIN; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN 2; CYTOTOXIN; VASCULOTROPIN A;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ARTICLE; ATHEROSCLEROTIC PLAQUE; BENIGN TUMOR; BLOOD VESSEL DIAMETER; BLOOD VESSEL FUNCTION; BRAIN METASTASIS; BREAST CANCER; CELLULAR STRESS SIGNAL; DOWN REGULATION; GLIOBLASTOMA; GLIOMA; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOTHERAPY; NEURILEMOMA; OXYGEN SENSING; PERIVASCULAR EPITHELIOID CELL TUMOR; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CARCINOMA; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM CARCINOMA; RENDU OSLER WEBER DISEASE; RETINA MACULA AGE RELATED DEGENERATION; SOLID TUMOR; TUMOR MICROENVIRONMENT; DISEASE COURSE; DRUG ANTAGONISM; MICROVASCULATURE; NEOPLASM; NEUROMA; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA MACULA DEGENERATION; REVIEW;

ANGIOGENESIS INHIBITORS; ANGIOPOIETIN-2; CYTOTOXINS; DISEASE PROGRESSION; HUMANS; MACULAR DEGENERATION; MICROVESSELS; NEOPLASMS; NEOVASCULARIZATION, PHYSIOLOGIC; NEUROMA, ACOUSTIC; PLAQUE, ATHEROSCLEROTIC; PSORIASIS; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84886675563     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a006486     Document Type: Article

References (188)

1. Abramsson A, Lindblom P, Betsholtz C. 2003. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest 112: 1142-1151.
2. Ader I, Delmas C, Bonnet J, Rochaix P, Favre G, Toulas C, Cohen-Jonathan-MoyalE. 2003. Inhibition of Rho pathways induces radiosensitization and oxygenation in human glioblastoma xenografts. Oncogene 22: 8861-8869.
3. Algire GH, Chalkley HW. 1945. Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J Natl Cancer Inst 6: 73-85.
4. Ansiaux R, Baudelet C, Jordan BF, Beghein N, Sonveaux P, De Wever J, Martinive P, Gregoire V, Feron O, Gallez B. 2005. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res 11: 743-750.
5. Ansiaux R, Baudelet C, Jordan BF, Crokart N, Martinive P, DeWever J, Gregoire V, Feron O, Gallez B. 2006. Mechanism of reoxygenation after antiangiogenic therapy using SU5416 and its importance for guiding combined antitumor therapy. Cancer Res 66: 9698-9704.
6. Augustin HG, Koh GY, Thurston G, Alitalo K. 2009. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 10: 165-177.
7. Bais C, Wu X, Yao J, Yang S, Crawford Y, McCutcheon K, Tan C, Kolumam G, Vernes JM, Eastham-Anderson J, et al. 2010. PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell 141: 166-177.
8. Baish JW, Stylianopoulos T, Lanning RM, Kamoun WS, Fukumura D, Munn LL, Jain RK. 2011. Scaling rules for diffusive drug delivery in tumor and normal tissues. Proc Natl Acad Sci 108: 1799-1803.
9. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, et al. 2007. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients [see comment]. Cancer Cell 11: 83-95.
10. Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, et al. 2010. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 28: 2817-2823.
11. Batra S, Matsumoto S, Hyodo F, Mitchell J, Krishna MC. 2009. MRI assessment of angiogenesis inhibitor Sunitinib's influence on tumor oxygenation to identify an optimal chemoradiotherapeutic window. Int J Radiat Oncol Biol Phys 75: S43.
12. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. 1999. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103: 159-165.
13. Bernsen HJ, Rijken PF, Peters JP, Bakker JH, Boerman RH, Wesseling P, van der Kogel AJ. 1999. Suramin treatment of human glioma xenografts; effects on tumor vasculature and oxygenation status. J Neurooncol 44: 129-136.
14. Bhattacharya A, Seshadri M, Oven SD, Toth K, Vaughan MM, Rustum YM. 2008. Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs. Clin Cancer Res 14: 3926-3932.
15. Bhattacharya A, Toth K, Sen A, Seshadri M, Cao S, Durrani FA, Faber E, RepaskyEA, Rustum YM. 2009. Inhibition of colon cancer growth by methylselenocysteine-induced angiogenic chemomodulation is influenced by histologic characteristics of the tumor. Clin Colorectal Cancer 8: 155-162.
16. Bielenberg DR, Pettaway CA, Takashima S, Klagsbrun M. 2006. Neuropilins in neoplasms: Expression, regulation, and function. Exp Cell Res 312: 584-593.
17. Bocci G, Francia G, Man S, Lawler J, Kerbel RS. 2003. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci 100: 12917-12922.
18. Bose P, Holter JL, Selby GB. 2009. Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 360: 2143-2144.
19. Boucher Y, Baxter LT, Jain RK. 1990. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: Implications for therapy. Cancer Res 50: 4478-4484.
20. Boucher Y, Kirkwood JM, Opacic D, Desantis M, Jain RK. 1991. Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res 51: 6691-6694.
21. Braverman IM, Yen A. 1977. Ultrastructure of the capillary loops in the dermal papillae of psoriasis. J Invest Dermatol 68: 53-60.
22. Bressler NM. 2009a. Antiangiogenic approaches to age-related macular degeneration today. Ophthalmology 116: S15-S23.
23. Bressler SB. 2009b. Introduction: Understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration. Ophthalmology 116: S1-S7.
24. Brieger J, Bedavanija A, Lehr HA, Maurer J, Mann WJ. 2003. Expression of angiogenic growth factors in acoustic neurinoma. Acta Otolaryngol 123: 1040-1045.
25. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J. 2000. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60: 1878-1886.
26. Bullitt E, Lin NU, Smith JK, Zeng D, Winer EP, Carey LA, Lin W, Ewend MG. 2007. Blood vessel morphologic changes depicted with MR angiography during treatment of brain metastases: A feasibility study. Radiology 245: 824-830.
27. Carmeliet P, Jain RK. 2011. Molecular mechanisms and clinical applications of angiogenesis. Nature 473: 298-307.
28. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H, et al. 2001. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7: 575-583.
29. Caye-Thomasen P, Baandrup L, Jacobsen GK, Thomsen J, Stangerup SE. 2003. Immunohistochemical demonstration of vascular endothelial growth factor in vestibular schwannomas correlates to tumor growth rate. Laryngoscope 113: 2129-2134.
30. Caye-Thomasen P, Werther K, Nalla A, Bog-Hansen TC, Nielsen HJ, StangerupSE, Thomsen J. 2005. VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate. Otol Neurotol 26: 98-101.
31. Cerniglia GJ, Pore N, Tsai JH, Schultz S, Mick R, Choe R, Xing X, Durduran T, Yodh AG, Evans SM, et al. 2009. Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy. PLoS One 4: e6539.
32. Chae SS, Kamoun WS, Farrar CT, Kirkpatrick ND, Niemeyer E, de Graaf AM, Sorensen AG, Munn LL, Jain RK, Fukumura D. 2010. Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas. Clin Cancer Res 16: 3618-3627.
33. Cham KK, Baker JH, Takhar KS, Flexman JA, Wong MQ, Owen DA, Yung A, Kozlowski P, Reinsberg SA, Chu EM, et al. 2010. Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma. Br J Cancer 103: 52-60.
34. Chung AS, Lee J, Ferrara N. 2010. Targeting the tumour vasculature: Insights from physiological angiogenesis. Nat Rev Cancer 10: 505-514.
35. Coffelt SB, Tal AO, Scholz A, De Palma M, Patel S, Urbich C, Biswas SK, Murdoch C, Plate KH, Reiss Y, et al. 2010. Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions. Cancer Res 70: 5270-5280.
36. Cohen-Jonathan E, Evans SM, Koch CJ, Muschel RJ, McKenna WG, Wu J, Bernhard EJ. 2001. The farnesyltransferase inhibitor L744, 832 reduces hypoxia in tumors expressing activated H-ras. Cancer Res 61: 2289-2293.
37. Creamer D, Allen MH, Sousa A, Poston R, Barker JN. 1997. Localization of endothelial proliferation and microvascular expansion in active plaque psoriasis. Br J Dermatol 136: 859-865.
38. Das PK, de Boer OJ, Visser A, Verhagen CE, Bos JD, Pals ST. 1994. Differential expression of ICAM-1, E-selectin and VCAM-1 by endothelial cells in psoriasis and contact dermatitis. Acta Derm Venereol Suppl (Stockh) 186: 21-22.
39. DeClerck K, Elble RC. 2010. The role of hypoxia and acidosis in promoting metastasis and resistance to chemotherapy. Front Biosci 15: 213-225.
40. Delmas C, End D, Rochaix P, Favre G, Toulas C, Cohen-Jonathan E. 2003. The farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft. Clin Cancer Res 9: 6062-6068.
41. Desgrosellier JS, Cheresh DA. 2010. Integrins in cancer: Biological implications and therapeutic opportunities. Nat Rev Cancer 10: 9-22.
42. Dickson PV, Hagedorn NL, Hamner JB, Fraga CH, Ng CY, Stewart CF, DavidoffAM. 2007a. Interferon β-mediated vessel stabilization improves delivery and efficacy of systemically administered topotecan in a murine neuroblastoma model. J Pediat Surg 42: 160-165.
43. Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CY, Rajasekeran S, HagedornNL, McCarville MB, Stewart CF, Davidoff AM. 2007b. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 13: 3942-3950.
44. Dickson PV, Hamner JB, Streck CJ, Ng CY, McCarville MB, Calabrese C, Gilbertson RJ, Stewart CF, Wilson CM, Gaber MW, et al. 2007c. Continuous delivery of IFN-β promotes sustained maturation of intratumoral vasculature. Molec Cancer Res 5: 531-542.
45. Dings RP, Loren M, Heun H, McNiel E, Griffioen AW, Mayo KH, Griffin RJ. 2007. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 13: 3395-3402.
46. Dirkx AE, oude Egbrink MG, Castermans K, van der Schaft DW, Thijssen VL, Dings RP, Kwee L, Mayo KH, Wagstaff J, Bouma-ter Steege JC, et al. 2006. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J 20: 621-630.
47. di Tomaso E, London N, Fuja D, Logie J, Tyrrell JA, Kamoun W, Munn LL, Jain RK. 2009. PDGF-C induces maturation of blood vessels in a model of glioblastoma and attenuates the response to anti-VEGF treatment. PLoS ONE 4: e5123.
48. di Tomaso E, Snuderl M, Kamoun WS, Duda DG, Auluck PK, Andronesi OC, Frosch MP, Wen PY, Plotkin SR, Hedley-Whyte ET, et al. 2011. Glioblastoma recurrence after Cediranib therapy in patients: Lack of "rebound" revascularization as mode of escape. Cancer Res 71: 19-28.
49. Duda DG, Willett CG, Ancukiewicz M, di Tomaso E, Shah M, Czito BG, BentleyR, Poleski M, Lauwers GY, Carroll M, et al. 2010. Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. Oncologist 15: 577-583.
50. Dvorak HF. 1986. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315: 1650-1659.
51. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. 2009. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15: 232-239.
52. Eichhorn ME, Strieth S, Luedemann S, Kleespies A, Noth U, Passon A, Brix G, Jauch KW, Bruns CJ, Dellian M. 2008. Contrast enhanced MRI and intravital fluorescence microscopy indicate improved tumor microcirculation in highly vascularized melanomas on short-term anti-VEGFR treatment [see comment]. Cancer Biol Ther 7: 1006-1013.
53. Eyetech Study Group. 2002. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 22: 143-152.
54. Falcon BL, Hashizume H, Koumoutsakos P, Chou J, Bready JV, Coxon A, OlinerJD, McDonald DM. 2009. Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am J Pathol 175: 2159-2170.
55. Ferrara N. 2005. VEGF as a therapeutic target in cancer. Oncology 69 (Suppl 3): 11-16.
56. Ferrara N. 2010. Vascular endothelial growth factor and age-related macular degeneration: From basic science to therapy. Nat Med 16: 1107-1111.
57. Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, Chorianopoulos E, Liesenborghs L, Koch M, De Mol M, et al. 2007. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131: 463-475.
58. Fischer I, Cunliffe CH, Bollo RJ, Raza S, Monoky D, Chiriboga L, Parker EC, Golfinos JG, Kelly PJ, Knopp EA, et al. 2008. High-grade glioma before and after treatment with radiation and Avastin: Initial observations [see comment]. Neuro-Oncology 10: 700-708.
59. Flieger D, Hainke S, Fischbach W. 2006. Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab. Ann Hematol 85: 631-632.
60. Folkman J. 1971. Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186.
61. Fournier C, Tisman G. 2010. Sorafenib-associated remission of psoriasis in hypernephroma: Case report. Dermatol Online J 16: 17.
62. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. 1995. Definition of two angiogenic pathways by distinct α v integrins. Science 270: 1500-1502.
63. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd. 2007. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25: 1539-1544.
64. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK. 2011. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91: 1071-1121.
65. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, Seetharam S, Koons A, Hari DM, Kufe DW, et al. 1999. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59: 3374-3378.
66. Gossl M, Versari D, Hildebrandt HA, Bajanowski T, Sangiorgi G, Erbel R, RitmanEL, Lerman LO, Lerman A. 2010. Segmental heterogeneity of vasa vasorum neovascularization in human coronary atherosclerosis. JACC Cardiovasc Imaging 3: 32-40.
67. Gragoudas ES, Adamis AP, Cunningham ET Jr., Feinsod M, Guyer DR. 2004. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351: 2805-2816.
68. Greenberg JI, Shields DJ, Barillas SG, Acevedo LM, Murphy E, Huang J, ScheppkeL, Stockmann C, Johnson RS, Angle N, et al. 2008. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 456: 809-813.
69. Griffioen AW, Damen CA, Blijham GH, Groenewegen G. 1996. Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. Blood 88: 667-673.
70. Gullino PM. 1982. Vascular normalization. In Biomedical thermology (ed. Gautherie M, Albert E). A. R. Liss, New York.
71. Hagendoorn J, Tong R, Fukumura D, Lin Q, Lobo J, Padera TP, Xu L, Kucherlapati R, Jain RK. 2006. Onset of abnormal blood and lymphatic vessel function and interstitial hypertension in early stages of carcinogenesis. Cancer Res 66: 3360-3364.
72. Hamzah J, Jugold M, Kiessling F, Rigby P, Manzur M, Marti HH, Rabie T, KadenS, Grone HJ, Hammerling GJ, et al. 2008. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 453: 410-414.
73. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100: 57-70.
74. Hansen-Algenstaedt N, Stoll BR, Padera TP, Dolmans DE, Hicklin DJ, FukumuraD, Jain RK. 2000. Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy. Cancer Res 60: 4556-4560.
75. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, Jain RK, McDonald DM. 2000. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156: 1363-1380.
76. Heidenreich R, Rocken M, Ghoreschi K. 2009. Angiogenesis drives psoriasis pathogenesis. Int J Exp Pathol 90: 232-248.
77. Herbst RS, Sun Y, Eberhardt WE, Germonpre P, Saijo N, Zhou C, Wang J, Li L, Kabbinavar F, Ichinose Y, et al. 2010. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): A double-blind, randomised, phase 3 trial. Lancet Oncol 11: 619-626.
78. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, Jain RK. 1998. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc Natl Acad Sci 95: 4607-4612.
79. Huang X, Wong MK, Yi H, Watkins S, Laird AD, Wolf SF, Gorelik E. 2002. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7. 2-IgG fusion protein. Cancer Res 62: 5727-5735.
80. Huang H, Bhat A, Woodnutt G, Lappe R. 2010. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 10: 575-585.
81. Huang Y, Snuderl M, Jain RK. 2011. Polarization of tumor-associated macrophages: a novel strategy for vascular normalization and antitumor immunity. Cancer Cell 19: 1-2.
82. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al. 2004. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342.
83. Ide AG, Baker NH, Warren SL. 1939. Vascularization of the Brown-Pearce rabbit epithelioma transplant as seen in the transparent ear chamber. Am J Radiol 42: 891-899.
84. Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, Hu-Lowe DD, Shalinsky DR, Thurston G, Yancopoulos GD, et al. 2004. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 165: 35-52.
85. Ishida S, Usui T, Yamashiro K, Kaji Y, Amano S, Ogura Y, Hida T, Oguchi Y, Ambati J, Miller JW, et al. 2003. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 198: 483-489.
86. Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK. 2002. Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature 416: 279-280.
87. Jain RK. 1988. Determinants of tumor blood flow: A review. Cancer Res 48: 2641-2658.
88. Jain RK. 1989. Delivery of novel therapeutic agents in tumors: Physiological barriers and strategies. J Natl Cancer Inst 81: 570-576.
89. Jain RK. 2001. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 7: 987-989.
90. Jain RK. 2003. Molecular regulation of vessel maturation. Nat Med 9: 685-693.
91. Jain RK. 2005a. Antiangiogenic therapy for cancer: Current and emerging concepts. Oncology (Williston Park) 19: 7-16.
92. Jain RK. 2005b. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307: 58-62.
93. Jain RK. 2008. Taming vessels to treat cancer. Sci Am 298: 56-63.
94. Jain RK, Booth MF. 2003. What brings pericytes to tumor vessels? J Clin Invest 112: 1134-1136.
95. Jain RK, Safabakhsh N, Sckell A, Chen Y, Jiang P, Benjamin L, Yuan F, Keshet E. 1998. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: Role of vascular endothelial growth factor. Proc Natl Acad Sci 95: 10820-10825.
96. Jain RK, Duda DG, Clark JW, Loeffler JS. 2006. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3: 24-40.
97. Jain RK, Finn AV, Kolodgie FD, Gold HK, Virmani R. 2007. Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: A potential strategy for plaque stabilization. Nat Clin Pract Cardiovasc Med 4: 491-502.
98. Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, Batchelor TT, Sorensen AG. 2009. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6: 327-338.
99. Jeziorska M, Woolley DE. 1999. Local neovascularization and cellular composition within vulnerable regions of atherosclerotic plaques of human carotid arteries. J Pathol 188: 189-196.
100. Johns TG, McKay MJ, Cvrljevic AN, Gan HK, Taylor C, Xu H, Smyth FE, Scott AM. 2010. MAb 806 enhances the efficacy of ionizing radiation in glioma xenografts expressing the de2-7 epidermal growth factor receptor. Int J Radiat Oncol Biol Phys 78: 572-578.
101. Juan TY, Roffler SR, Hou HS, Huang SM, Chen KC, Leu YL, Prijovich ZM, Yu CP, Wu CC, Sun GH, et al. 2009. Antiangiogenesis targeting tumor microenvironment synergizes glucuronide prodrug antitumor activity. Clin Cancer Res 15: 4600-4611.
102. Kamoun WS, Ley CD, Farrar CT, Duyverman AM, Lahdenranta J, Lacorre DA, Batchelor TT, di Tomaso E, Duda DG, Munn LL, et al. 2009. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 27: 2542-2552.
103. Kamoun WS, Chae SS, Lacorre DA, Tyrrell JA, Mitre M, Gillissen MA, FukumuraD, Jain RK, Munn LL. 2010. Simultaneous measurement of RBC velocity, flux, hematocrit and shear rate in vascular networks. Nat Methods 7: 655-660.
104. Kashiwagi S, Izumi Y, Gohongi T, Demou ZN, Xu L, Huang PL, Buerk DG, MunnLL, Jain RK, Fukumura D. 2005. NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels. J Clin Invest 115: 1816-1827.
105. Kashiwagi S, Tsukada K, Xu L, Miyazaki J, Kozin SV, Tyrrell JA, Sessa WC, Gerweck LE, Jain RK, Fukumura D. 2008. Perivascular nitric oxide gradients normalize tumor vasculature. Nat Med 14: 255-257.
106. Kerbel RS, Kamen BA. 2004. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4: 423-436.
107. Keshtgarpour M, Dudek AZ. 2007. SU-011248, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor, controls chronic psoriasis. Trans Res 149: 103-106.
108. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. 1993. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844.
109. Koh YJ, Kim HZ, Hwang SI, Lee JE, Oh N, Jung K, Kim M, Kim KE, Kim H, Lim NK, et al. 2010. Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell 18: 171-184.
110. Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, Farb A, Guerrero LJ, Hayase M, Kutys R, et al. 2003. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 349: 2316-2325.
111. Kozin SV, Boucher Y, Hicklin DJ, Bohlen P, Jain RK, Suit HD. 2001. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res 61: 39-44.
112. Kurozumi K, Hardcastle J, Thakur R, Yang M, Christoforidis G, Fulci G, Hochberg FH, Weissleder R, Carson W, Chiocca EA, et al. 2007. Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst 99: 1768-1781.
113. Lebrin F, Srun S, Raymond K, Martin S, van den Brink S, Freitas C, Breant C, Mathivet T, Larrivee B, Thomas JL, et al. 2010. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med 16: 420-428.
114. Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, Park KR, Ferrara N, Jain RK, Suit HD, et al. 2000. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60: 5565-5570.
115. Less JR, Skalak TC, Sevick EM, Jain RK. 1991. Microvascular architecture in a mammary carcinoma: Branching patterns and vessel dimensions. Cancer Res 51: 265-273.
116. Less JR, Posner MC, Boucher Y, Borochovitz D, Wolmark N, Jain RK. 1992. Interstitial hypertension in human breast and colorectal tumors. Cancer Res 52: 6371-6374.
117. Less JR, Posner MC, Skalak TC, Wolmark N, Jain RK. 1997. Geometric resistance and microvascular network architecture of human colorectal carcinoma. Microcirculation 4: 25-33.
118. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. 1989. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306-1309.
119. Leunig M, Yuan F, Menger MD, Boucher Y, Goetz AE, Messmer K, Jain RK. 1992. Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice. Cancer Res 52: 6553-6560.
120. Li B, Lalani AS, Harding TC, Luan B, Koprivnikar K, Huan Tu G, Prell R, VanRoeyMJ, Simmons AD, et al. 2006. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin Cancer Res 12: 6808-6816.
121. Liao S, Liu J, Lin P, Jain RK, Xu L. 2011. TGF-β blockade controls ascites by preventing abnormalization of lymphatic vessels in an orthotopic human ovarian carcinoma models. Clin Cancer Res 17: 1415-1424.
122. Liu F, Wang P, Jiang X, Tan G, Qiao H, Jiang H, Krissansen GW, Sun X. 2008. Antisense hypoxia-inducible factor 1α gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma. Cancer Sci 99: 2055-2061.
123. Lu-Emerson C, Plotkin SR. 2009. The neurofibromatoses. Part 2: NF2 and schwannomatosis. Rev Neurol Dis 6: E81-E86.
124. Maione F, Molla F, Meda C, Latini R, Zentilin L, Giacca M, Seano G, Serini G, Bussolino F, Giraudo E. 2009. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks growth and normalizes the vasculature. J Clin Invest 119: 3356-3372.
125. Manning EA, Ullman JG, Leatherman JM, Asquith JM, Hansen TR, Armstrong TD, Hicklin DJ, Jaffee EM, Emens LA. 2007. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin Cancer Res 13: 3951-3959.
126. Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A, Pliti LS, Gentner B, Brown JL, Naldini L, De Palma M. 2011. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 19: 512-526.
127. Mazzone M, Dettori D, Leite de Oliveira R, Loges S, Schmidt T, Jonckx B, TianYM, Lanahan AA, Pollard P, Ruiz de Almodovar C, et al. 2009. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization [see comment]. Cell 136: 839-851.
128. McCarty MF, Somcio RJ, Stoeltzing O, Wey J, Fan F, Liu W, Bucana C, Ellis LM. 2007. Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. J Clin Invest 117: 2114-2122.
129. McGee MC, Hamner JB, Williams RF, Rosati SF, Sims TL, Ng CY, Gaber MW, Calabrese C, Wu J, Nathwani AC, et al. 2010. Improved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiation. Int J Radiat Oncol Biol Phys 76: 1537-1545.
130. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, CellaD, Davidson NE. 2007. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357: 2666-2676.
131. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM. 2002. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 160: 985-1000.
132. Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J. 1999. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 99: 1726-1732.
133. Nagy JA, Chang SH, Dvorak AM, Dvorak HF. 2009. Why are tumour blood vessels abnormal and why is it important to know? Br J Cancer 100: 865-869.
134. Nakahara T, Norberg SM, Shalinsky DR, Hu-Lowe DD, McDonald DM. 2006. Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. Cancer Res 66: 1434-1445.
135. Narayanan S, Callis-Duffin K, Batten J, Agarwal N. 2010. Improvement of psoriasis during sunitinib therapy for renal cell carcinoma. Am J Med Sci 339: 580-581.
136. Nasarre P, Thomas M, Kruse K, Helfrich I, Wolter V, Deppermann C, Schadendorf D, Thurston G, Fiedler U, Augustin HG. 2009. Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res 69: 1324-1333.
137. Ohta M, Kawabata T, Yamamoto M, Tanaka T, Kikuchi H, Hiramatsu Y, Kamiya K, Baba M, Konno H. 2009. TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model. Surg Today 39: 1046-1053.
138. Padera TP, Stoll BR, Tooredman JB, Capen D, di Tomaso E, Jain RK. 2004. Pathology: Cancer cells compress intratumour vessels. Nature 427: 695.
139. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O. 2009. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231.
140. Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd., Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, di Tomaso E. 2009. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 361: 358-367.
141. Pore N, Gupta AK, Cerniglia GJ, Jiang Z, Bernhard EJ, Evans SM, Koch CJ, HahnSM, Maity A. 2006a. Nelfinavir down-regulates hypoxia-inducible factor 1α and VEGF expression and increases tumor oxygenation: implications for radiotherapy. Cancer Res 66: 9252-9259.
142. Pore N, Jiang Z, Gupta A, Cerniglia G, Kao GD, Maity A. 2006b. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res 66: 3197-3204.
143. Primo L, Seano G, Roca C, Maione F, Gagliardi PA, Sessa R, Martinelli M, Giraudo E, di Blasio L, Bussolino F. 2010. Increased expression of α6 integrin in endothelial cells unveils a proangiogenic role for basement membrane. Cancer Res 70: 5759-5769.
144. Qayum N, Muschel RJ, Im JH, Balathasan L, Koch CJ, Patel S, McKenna WG, Bernhard EJ. 2009. Tumor vascular changes mediated by inhibition of oncogenic signaling. Cancer Res 69: 6347-6354.
145. Rajappa M, Saxena P, Kaur J. 2010. Ocular angiogenesis: mechanisms and recent advances in therapy. Adv Clin Chem 50: 103-121.
146. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, et al. 2009. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27: 1227-1234.
147. Roh HD, Boucher Y, Kalnicki S, Buchsbaum R, Bloomer WD, Jain RK. 1991. Interstitial hypertension in carcinoma of uterine cervix in patients: Possible correlation with tumor oxygenation and radiation response. Cancer Res 51: 6695-6698.
148. Rolny C, Mazzone M, Tugues S, Laoui D, Johannson I, Couon C, Squadrito ML, Segura I, Li X, Knevels E, et al. 2011. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 19: 31-44.
149. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY. 2006. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419-1431.
150. Salnikov AV, Roswall P, Sundberg C, Gardner H, Heldin NE, Rubin K. 2005. Inhibition of TGF-β modulates macrophages and vessel maturation in parallel to a lowering of interstitial fluid pressure in experimental carcinoma. Lab Invest 85: 512-521.
151. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, et al. 2008. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26: 2013-2019.
152. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. 2006. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542-2550.
153. Schnell CR, Stauffer F, Allegrini PR, O'Reilly T, McSheehy PM, Dartois C, StummM, Cozens R, Littlewood-Evans A, Garcia-Echeverria C, et al. 2008. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: Implications for clinical imaging. Cancer Res 68: 6598-6607.
154. Schonthaler HB, Huggenberger R, Wculek SK, Detmar M, Wagner EF. 2009. Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis. Proc Natl Acad Sci 106: 21264-21269.
155. Segers J, Di Fazio V, Ansiaux R, Martinive P, Feron O, Wallemacq P, Gallez B. 2006. Potentiation of cyclophosphamide chemotherapy using the anti-angiogenic drug thalidomide: importance of optimal scheduling to exploit the "normalization" window of the tumor vasculature. Cancer Lett 244: 129-135.
156. Semenza GL. 2010. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29: 625-634.
157. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. 1983. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983-985.
158. Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. 2010. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 70: 6171-6180.
159. Skuli N, Monferran S, Delmas C, Favre G, Bonnet J, Toulas C, Cohen-Jonathan Moyal E. 2009. αvβ3/αvβ5 integrins-FAK-RhoB: A novel pathway for hypoxia regulation in glioblastoma. Cancer Res 69: 3308-3316.
160. Sorensen AG, Batchelor TT, Zhang WT, Chen PJ, Yeo P, Wang M, Jennings D, Wen PY, Lahdenranta J, Ancukiewicz M, et al. 2009. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 69: 5296-5300.
161. Stockmann C, Doedens A, Weidemann A, Zhang N, Takeda N, Greenberg JI, Cheresh DA, Johnson RS. 2008. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 456: 814-818.
162. Stohrer M, Boucher Y, Stangassinger M, Jain RK. 2000. Oncotic pressure in solid tumors is elevated. Cancer Res 60: 4251-4255.
163. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD. 1996. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87: 1171-1180.
164. Taguchi E, Nakamura K, Miura T, Shibuya M, Isoe T. 2008. Anti-tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model. Cancer Sci 99: 623-630.
165. Taylor KL, Leaman DW, Grane R, Mechti N, Borden EC, Lindner DJ. 2008. Identification of interferon-β-stimulated genes that inhibit angiogenesis in vitro. J Interferon Cytokine Res 28: 733-740.
166. Teicher BA. 1996. A systems approach to cancer therapy (antioncogenics+standard cytotoxics→mechanism(s) of interaction). Cancer Metastasis Rev 15: 247-272.
167. Teicher BA, Dupuis NP, Robinson MF, Emi Y, Goff DA. 1995a. Antiangiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma. Oncol Res 7: 237-243.
168. Teicher BA, Holden SA, Dupuis NP, Kakeji Y, Ikebe M, Emi Y, Goff D. 1995b. Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma. Breast Cancer Res Treat 36: 227-236.
169. Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD, McDonaldDM. 1999. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286: 2511-2514.
170. Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, Glazer N, Holash J, McDonald DM, Yancopoulos GD. 2000. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nature Med 6: 460-463.
171. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. 2004. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64: 3731-3736.
172. Tsukada K, Conner D, Lin Q, Kucherlapati R, Jain RK, Fukumura D. 2009. Blockade of inducible nitric oxide synthase normalizes murine breast cancer vessels. In100th Annual Meeting of AACR, Denver, CO.
173. Van de Veire S, Stalmans I, Heindryckx F, Oura H, Tijeras-Raballand A, Schmidt T, Loges S, Albrecht I, Jonckx B, Vinckier S, et al. 2010. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 141: 178-190.
174. Virmani R, Kolodgie FD, Burke AP, Finn AV, Gold HK, Tulenko TN, Wrenn SP, Narula J. 2005. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 25: 2054-2061.
175. Vogelstein B, Kinzler KW. 2004. Cancer genes and the pathways they control. Nat Med 10: 789-799.
176. Wildiers H, Guetens G, De Boeck G, Verbeken E, Landuyt B, Landuyt W, de Bruijn EA, van Oosterom AT. 2003. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 88: 1979-1986.
177. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, et al. 2004. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10: 145-147.
178. Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, Kozin SV, Petit L, Jain RK, Chung DC, et al. 2005. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 23: 8136-8139.
179. Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, Lahdenranta J, Chung DC, Fischman AJ, Lauwers GY, et al. 2009. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: A multidisciplinary phase II study. J Clin Oncol 27: 3020-3026.
180. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, HicklinDJ, Fukumura D, di Tomaso E, et al. 2004. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases [see comment]. Cancer Cell 6: 553-563.
181. Wong HK, Lahdenranta J, Kamoun WS, Chan AW, McClatchey AI, Plotkin SR, JainRK, di Tomaso E. 2010. Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors. Cancer Res 70: 3483-3493.
182. Xian X, Hakansson J, Stahlberg A, Lindblom P, Betsholtz C, Gerhardt H, Semb H. 2006. Pericytes limit tumor cell metastasis. J Clin Invest 116: 642-651.
183. Xue Q, Hopkins B, Perruzzi C, Udayakumar D, Sherris D, Benjamin LE. 2008. Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability. Cancer Res 68: 9551-9557.
184. Yu J, deMuinck ED, Zhuang Z, Drinane M, Kauser K, Rubanyi GM, Qian HS, Murata T, Escalante B, Sessa WC. 2005. Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment, and blood flow reserve. Proc Natl Acad Sci 102: 10999-11004.
185. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. 1996. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci 93: 14765-14770.
186. Zhou Q, Gallo JM. 2009. Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model. Neuro-Oncology 11: 301-310.
187. Zhou Q, Guo P, Gallo JM. 2008. Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide [erratum appears in Clin Cancer Res, 2008 Aug 15; 14(16): 5308-9]. Clin Cancer Res 14: 1540-1549.
188. Zibert JR, Wallbrecht K, Schon M, Mir LM, Jacobsen GK, Trochon-Joseph V, Bouquet C, Villadsen LS, Cadossi R, Skov L, et al. 2010. Halting angiogenesis by non-viral somatic gene therapy alleviates psoriasis and murine psoriasiform skin lesions. J Clin Invest 121: 410-421.